Combining ferroptosis inducers with gemcitabine to enhance treatment efficacy in pancreatic cancer
{{output}}
Background: Gemcitabine (GEM) is a standard chemotherapy for pancreatic cancer, but resistance limits its clinical benefit. The role of SRRM1, a splicing regulator, in GEM resistance remains unclear. ... ...
